Novartis and Alnylam form RNA interference alliance
9th Sep 2005, 02:03 GMT
Novartis and Alnylam Pharmaceuticals have formed a multi-year alliance focused on the discovery of innovative therapeutics based on a process called RNA interference, which treats disease by inhibiting and regulating the activity of specific genes.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol